The University of Sheffield
Browse

The cost-effectiveness of expanding the NHS newborn bloodspot screening programme to include homocystinuria (HCU), maple syrup urine disease (MSUD), glutaric aciduria type 1 (GA1), isovaleric acidaemia (IVA), and long-chain hydroxyl acyl-CoA dehydrogenase deficiency (LCHADD) (2014)

Download (420.33 kB)
poster
posted on 2020-03-01, 12:08 authored by Alice Bessey, Jim Chilcott, Suzy Paisley, Abdullah PandorAbdullah Pandor
The NHS newborn bloodspot screening programme screens all babies in England for five rare conditions. This study assessed the economics of expanding the screening programme to include five new inborn errors of the metabolism; HCU, MSUD, GA1, IVA, and LCHADD.

History

Ethics

  • There is no personal data or any that requires ethical approval

Policy

  • The data complies with the institution and funders' policies on access and sharing

Sharing and access restrictions

  • The data can be shared openly

Data description

  • The file formats are open or commonly used

Methodology, headings and units

  • Headings and units are explained in the files

Usage metrics

    The University of Sheffield

    Categories

    Keywords

    NHSnewborn bloodspot screening programmeMaple syrup urine diseaseglutaric aciduria type 1 (GA1)isovaleric acidaemia (IVA)long chain hydroxyl acyl-CoA dehydrogenase deficiency (LCHADD)Health Economics

    Licence

    CC BY 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC